Consensus Ocular Therapeutix, Inc.

Stocks

OCUL

US67576A1007

Pharmaceuticals

Real-time Estimate Cboe BZX 22:57:09 02/11/2026 +04			5-day change	1st Jan Change
6.720 ^USD	-3.59%		+4.02%	-44.56%

10-24	Ocular Therapeutix, Inc. - Special Call
10-20	Ocular Therapeutix Has 75% Success Probability for Axpaxli in Wet Age-Related Macular Degeneration, UBS Says	MT

Evolution of the Average Target: Ocular Therapeutix, Inc.

Evolution of the Target Price: Ocular Therapeutix, Inc.

Changes in Analyst Recommendations: Ocular Therapeutix, Inc.

aa584dfccf15ba53376408dc4d504188.X-7vu9UmEz8lHwhfQ3rC1A0JtZC_HGyFSAviSz-IYCI.NZSFzYVgWnZ0eFtmKAi6pGFsh8eIKC3dPXiIGH7BOGU8oYvvn2BSUX1xTQ~289e2b8e98fa99a5b57e0f141b67f6fa

Analysts' recommendations: Ocular Therapeutix, Inc.

10-20	Ocular Therapeutix Has 75% Success Probability for Axpaxli in Wet Age-Related Macular Degeneration, UBS Says	MT
10-12	UBS Initiates Coverage on Ocular Therapeutix With Buy Rating, $14 Price Target	MT
08-04	Ocular Therapeutix's NDA Plans for Axpaxli in Wet AMD Remain on Track, RBC Says	MT
06-25	Chardan Raises Price Target on Ocular Therapeutix to $23 From $21, Keeps Buy Rating	MT
05-06	Ocular Therapeutix Advances FDA Talks on Single-Trial Filing for Eye Drug, RBC Says	MT
12-16	RBC Capital Adjusts Ocular Therapeutix Price Target to $24 From $17, Maintains Outperform Rating	MT
01/10/25	Ocular Therapeutix's Axpaxli Drug Trials for Wet AMD Poised for Success, RBC Capital Says	MT
30/09/25	Ocular Therapeutix, Inc. Announces Updates Regarding Its Development Programs for AXPAXLI	CI
15/09/25	Chardan Capital Initiates Ocular Therapeutix at Buy With $21 Price Target	MT
08/04/25	William Blair Initiates Ocular Therapeutix With Outperform Rating	MT
18/03/25	RBC Initiates Ocular Therapeutix at Outperform, Speculative Risk With $17 Price Target	MT
11/03/25	Needham Initiates Ocular Therapeutix at Buy With $15 Price Target	MT
16/10/24	Scotiabank Initiates Ocular Therapeutix at Sector Outperform	MT
20/06/24	TD Cowen Upgrades Ocular Therapeutix to Buy From Hold, Adjusts Price Target to $11 From $7	MT
31/05/24	Piper Sandler Starts Ocular Therapeutix With Overweight Rating, $15 Price Target	MT
13/03/24	HC Wainwright Adjusts Price Target on Ocular Therapeutix to $15 From $12, Keeps Buy Rating	MT
12/03/24	TD Cowen Adjusts Price Target on Ocular Therapeutix to $11 From $8, Maintains Market Perform Rating	MT
12/03/24	JMP Securities Adjusts Ocular Therapeutix's Price Target to $24 From $12, Maintains Market Outperform Rating	MT
26/02/24	Piper Sandler Adjusts Ocular Therapeutix Price Target to $15 From $10, Maintains Overweight Rating	MT
13/06/23	HC Wainwright Adjusts Ocular Therapeutix Price Target to $12 From $10, Maintains Buy Rating	MT
09/05/23	HC Wainwright Adjusts Price Target on Ocular Therapeutix to $10 From $11, Maintains Buy Rating	MT
09/05/23	JMP Securities Adjusts Price Target on Ocular Therapeutix to $12 From $11, Keeps Market Outperform Rating	MT
21/04/23	Baird Initiates Ocular Therapeutix at Outperform With $18 Price Target	MT
07/03/23	JMP Securities Adjusts Price Target on Ocular Therapeutix to $11 From $12, Maintains Market Outperform Rating	MT
14/02/23	HC Wainwright Adjusts Price Target on Ocular Therapeutix to $11 From $9, Maintains Buy Rating	MT

More recommendations

Other Pharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	OCULAR THERAPEUTIX, INC.					+265.2%
	ELI LILLY AND COMPANY					+0.25%
	JOHNSON & JOHNSON					+2.27%
	ABBVIE INC.					+0.77%
	ROCHE HOLDING AG					-2.72%
	MERCK & CO., INC.					+6.95%
	NOVARTIS AG					-5.37%
	ASTRAZENECA PLC					+12.86%
	AMGEN INC.					-14.74%
	GILEAD SCIENCES, INC.					+1.07%
	Average					+26.65%
	Weighted average by Cap.					+0.64%